Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887054 | 1.00 | ADORA1 (0.53) | ADORA1RNASEL | |
| SCHEMBL19887049 | 0.93 | ADORA1 (0.51) | ADORA1RNASEL | |
| SCHEMBL15280876 | 0.93 | ADORA1 (0.51) | ADORA1RNASEL | |
| SCHEMBL15280847 | 0.93 | ADORA1 (0.55) | ADORA1RNASEL | |
| SCHEMBL15280855 | 0.93 | ADORA1 (0.55) | ADORA1RNASEL | |
| SCHEMBL22060530 | 0.93 | ADORA1 (0.55) | ADORA1RNASEL | |
| SCHEMBL22292292 | 0.89 | RNASEL (0.60) | ADORA1RNASEL | |
| SCHEMBL15280878 | 0.89 | RNASEL (0.60) | ADORA1RNASEL | |
| SCHEMBL19887071 | 0.89 | RNASEL (0.60) | ADORA1RNASEL | |
| SCHEMBL15280831 | 0.86 | ADORA1 (0.48) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | ADORA1 1034/4885RNASEL 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.